MNTA Does seem to have or should be able to obtain enox patents with claim language for production despite the cafc decision which concerns just the analysis patent. Just a minor matter of claim language potentially. The patents could be a convenient and legal pretext underlying a settlement. Ie if Amphastar could be kicked out of the market there could be enough incentive to get back to duopoly?
Teva is a good fit. I think FDA's complete response letter on hospira's epo suggests that analytical characterization data is as important as clinical data for FDA. Should be very interesting to see which company partners with MNTA.
Market Data 
Markets 
AI
